A

Amgen

Makes biotech medicines for serious illnesses

Financial Planning & Business Analysis Senior Manager

Full-TimeUpdated on 10/24/2026
€82.3k - €111.3k
Expert
Bachelor's
Paris, France
In PersonOn-site in Paris.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A degree in Economics or Business Administration.
  • More than 8–10 years of experience working in a similar position in an international environment; pharmaceutical-industry experience is preferred.
  • Two to three years of experience in a management position within an international finance department is an asset.
  • Two to three years of accounting experience and five to six years of budgeting and planning experience.
  • Excellent user of Office programs, including Word, Excel, and PowerPoint.
  • Basic knowledge of applicable business administration and tax laws, especially value-added tax, as well as accounting and consolidation.
  • Basic knowledge of United States generally accepted accounting principles.
  • Ability to translate business strategy into financial plans, performance targets, and resource allocation decisions.
  • Strong business acumen and understanding of commercial, operational, and market drivers.
  • Advanced communication skills and ability to simplify complex financial issues for diverse audiences.
  • Ability to collaborate, build partnerships, and influence stakeholders across functions and levels.
  • Ability to negotiate and challenge constructively to drive business decisions and financial outcomes.
  • Ability to apply critical thinking and scenario analysis to identify risks, opportunities, and solutions.
  • Ability to lead with empathy and inclusivity, fostering collaboration, accountability, and continuous improvement.
  • Ability to develop and coach local and international team members, building organizational capability and succession readiness.
  • Ability to lead finance transformation, process optimization, and automation initiatives.
  • Ability to learn quickly and motivate others to adapt to new systems, processes, technologies, and ways of working.
  • Strong project management, planning, and organizational skills.
  • Ability to model Amgen values and foster an inclusive, ethical, and patient-focused culture.
Responsibilities
  • Lead, develop, and manage a team of four finance professionals, including two local direct reports and two Amgen Capability Center Portugal analysts, ensuring capability building, engagement, and high-quality delivery.
  • Own the affiliate forecasting, budgeting, and long-range planning processes and be accountable for forecast accuracy and financial performance visibility.
  • Act as a strategic advisor to the Leadership Team, translating financial insights into business decisions.
  • Partner with Commercial, Medical, Access, Human Resources, and Supply Chain leaders to drive business performance and resource allocation decisions.
  • Coordinate affiliate planning activities with ELMAC regional consolidation and planning teams.
  • Lead strategic planning, investment evaluation, and scenario modelling to support business decisions.
  • Lead forecasting of revenue, expenses, and operating profit, identifying risks and opportunities.
  • Partner with Value & Access to assess pricing strategies, market access risks, and financial implications.
  • Oversee monitoring of actual and forecasted costs and revenues on a monthly, quarterly, and annual basis.
  • Coordinate and consolidate the budget, latest estimate, and variance analysis.
  • Lead long-term planning activities, including Long Range Scenario.
  • Influence strategic decisions through financial insights and challenge-based discussions.
  • Deliver financial insights and performance reporting to the Affiliate Management Team and broader organization.
  • Lead finance transformation, process improvement, and automation initiatives.
Desired Qualifications
  • Experience in the pharmaceutical environment.
  • Experience with Diagnostics, Hyperion, Anaplan, SAP, CODEX, and artificial intelligence.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.